NextPlat Corp Common Stock

NextPlat Corp Common Stock Q3 2026 Earnings Recap

NXPL Q3 2026 Published November 15, 2026

Get alerts when NXPL reports next quarter

Set up alerts — free

NextPlat shares fell 15.3% after the earnings release, with the transcript pointing to ongoing pressure in retail pharmacy revenue and a sequential $0.3 million decline in medication-fulfillment contracts after a customer closed a facility. Management also delayed the healthcare e-commerce launch to this month, tempering the turnaround narrative despite year-over-year improvement in margins and operating losses.

Earnings Per Share Beat
$-0.28 vs $-0.46 est.
+39.1% surprise
Revenue Miss
10499000 vs 13000000 est.
-19.2% surprise

Market Reaction

Post-Earnings -15.32%

See NXPL alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • Contracted pharmacy revenue was nearly 300% higher year over year, but one customer’s facility closure reduced medication-fulfillment revenue by about $0.3 million sequentially.
  • Total pharmacy prescription revenue declined year over year, reflecting lower payer reimbursement rates, fewer prescriptions, and payer mix.
  • NextPlat added three 340B contracts in the quarter, bringing the annual total to 14; management said onboarding typically takes around 90 days.
  • The Scott’s Pharmacy acquisition is expected to contribute about $1.2 million in quarterly revenue and $150,000 in net profit during Q4, based on current activity.
  • The healthcare e-commerce site launch slipped from the expected Q3 timing and is now expected this month.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NXPL on AllInvestView.

Get the Full Picture on NXPL

Track NextPlat Corp Common Stock in your portfolio with real-time analytics, dividend tracking, and more.

View NXPL Analysis